Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating Costs and Expenses:
General and administrative	$ 212,000	$ 2,416,000	$ 5,099,000	$ 5,612,000
Research and development	4,006,000	2,570,000	10,115,000	8,652,000
Total Operating Costs and Expenses	4,218,000	4,986,000	15,214,000	14,264,000
Loss from Operations	(4,218,000)	(4,986,000)	(15,214,000)	(14,264,000)
Other Expense:
Exchange gain (loss)	6,000	(9,000)	7,000	(40,000)
Interest income	382,000	170,000	1,127,000	197,000
Total Other Income (Expense)	388,000	161,000	1,134,000	157,000
Net Loss Before Income Taxes	(3,830,000)	(4,825,000)	(14,080,000)	(14,107,000)
Income tax benefit	527,000	335,000	1,216,000	867,000
Net Loss Attributable to Theriva Biologics, Inc. and Subsidiaries	(3,303,000)	(4,490,000)	(12,864,000)	(13,240,000)
Effect of Warrant exercise price adjustment		(340,000)		(340,000)
Net Loss Attributable to Common Stockholders	$ (3,303,000)	$ (4,830,000)	$ (12,864,000)	$ (13,580,000)
Net Loss Per Share - Basic	$ (0.19)	$ (0.30)	$ (0.81)	$ (0.87)
Net Loss Per Share - Diluted	$ (0.19)	$ (0.30)	$ (0.81)	$ (0.87)
Weighted average number of shares outstanding during the period - Basic	17,042,701	15,844,061	15,784,685	15,176,927
Weighted average number of shares outstanding during the period - Diluted	17,042,701	15,844,061	15,784,685	15,176,927
Net Loss	$ (3,303,000)	$ (4,490,000)	$ (12,864,000)	$ (13,240,000)
Loss on foreign currency translation	(702,000)	(1,527,000)	(379,000)	(2,844,000)
Total comprehensive loss	$ (4,005,000)	$ (6,017,000)	$ (13,243,000)	$ (16,084,000)